Zacks Upgrades Inteliquent to Outperform (IQNT)

Share on StockTwits

Inteliquent (NASDAQ:IQNT) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Tuesday, ARN reports. The firm currently has a $15.20 price objective on the stock. Zacks‘s target price points to a potential upside of 11.44% from the stock’s previous close.

Inteliquent (NASDAQ:IQNT) opened at 13.64 on Tuesday. Inteliquent has a 52 week low of $4.35 and a 52 week high of $15.31. The stock has a 50-day moving average of $14.07 and a 200-day moving average of $12.30. The company has a market cap of $440.1 million and a P/E ratio of 8.00.

Inteliquent (NASDAQ:IQNT) last released its earnings data on Thursday, May 1st. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.23 by $0.05. The company had revenue of $56.20 million for the quarter, compared to the consensus estimate of $50.63 million. During the same quarter in the prior year, the company posted $0.21 earnings per share. The company’s quarterly revenue was down 5.2% on a year-over-year basis. On average, analysts predict that Inteliquent will post $0.90 earnings per share for the current fiscal year.

Inteliquent Inc, formerly Neutral Tandem, Inc, doing business as Inteliquent provides solutions for voice, data, and hosted services globally.

To view Zacks’ full report, visit Zacks’ official website.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

PharmAthene Short Interest Up 6.4% in August
PharmAthene Short Interest Up 6.4% in August
Short Interest in Midway Gold Corp. Grows By 16.3%
Short Interest in Midway Gold Corp. Grows By 16.3%
Orchid Island Capital Short Interest Up 23.0% in August
Orchid Island Capital Short Interest Up 23.0% in August
Franklin Street Properties Corp. Sees Significant Growth in Short Interest
Franklin Street Properties Corp. Sees Significant Growth in Short Interest
Inovio Pharmaceuticals Short Interest Up 2.5% in August
Inovio Pharmaceuticals Short Interest Up 2.5% in August
Recent Investment Analysts’ Ratings Updates for Toll Brothers
Recent Investment Analysts’ Ratings Updates for Toll Brothers


Leave a Reply

 
© 2006-2014 Mideast Time.